Kades & Cheifetz LLC Invests $41,000 in Arbutus Biopharma Co. (NASDAQ:ABUS)

Kades & Cheifetz LLC bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $41,000. A number of […]

Related Keywords

United States , ,Exchange Commission ,Arbutus Biopharma Corporation ,Nasdaq ,Nuveen Asset Management ,Wells Fargo Company ,Sg Americas Securities ,Arbutus Biopharma Co ,Kades Cheifetz ,Clear Harbor Asset Management ,Arbutus Biopharma ,Free Report ,Harbor Asset Management ,Asset Management ,Wells Fargo ,Get Free Report ,Biopharma Corporation ,Visit Holdingschannel ,Arbutus Biopharma Daily ,Nasdaq Abus ,Mabus ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,